Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Sonnet Biotherapeutics Holding - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SONN
Nasdaq
2834
https://www.sonnetbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Sonnet Biotherapeutics Holding
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
- Mar 19th, 2024 11:30 am
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
- Mar 11th, 2024 11:30 am
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
- Feb 29th, 2024 9:05 pm
Sonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectations
- Feb 17th, 2024 2:06 pm
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
- Feb 14th, 2024 12:30 pm
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
- Dec 21st, 2023 1:00 pm
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
- Dec 14th, 2023 9:15 pm
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
- Oct 31st, 2023 11:30 am
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
- Oct 25th, 2023 11:30 am
Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
- Oct 17th, 2023 12:00 pm
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
- Sep 20th, 2023 11:30 am
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
- Sep 19th, 2023 12:30 pm
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split
- Aug 31st, 2023 2:55 pm
Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
- Aug 16th, 2023 11:30 am
Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update
- Aug 14th, 2023 12:00 pm
Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
- Jul 31st, 2023 1:00 pm
Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement
- Jun 28th, 2023 12:00 pm
Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy
- Jun 23rd, 2023 12:00 pm
Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab
- Jun 20th, 2023 12:00 pm
Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
- May 10th, 2023 11:30 am
Scroll